Boston Scientific

Boston Scientific Corporation, a leader in the electromedical and electrotherapeutic apparatus manufacturing industry, has established significant commitments to reduce its carbon emissions and combat climate change.

For the year 2024, the company reported a total of approximately 1.79 billion kg CO2e in emissions. This figure is comprised of Scope 1 emissions amounting to approximately 87.57 million kg CO2e, and Scope 2 emissions (market-based) of about 9.85 million kg CO2e. The company also reported Scope 3 emissions totalling approximately 1.66 billion kg CO2e. These Scope 3 emissions are predominantly driven by purchased goods and services, which accounted for approximately 947 million kg CO2e, and upstream transportation and distribution, contributing around 201 million kg CO2e.

Boston Scientific has set ambitious targets aligned with climate science. The company aims for a 46.2% absolute reduction in Scope 1 and 2 greenhouse gas (GHG) emissions by 2030, using 2019 as a baseline year. Furthermore, they are committed to a 55% reduction in Scope 3 GHG emissions per USD value added by 2030, also from a 2019 baseline. For the longer term, Boston Scientific has a net-zero commitment for its value chain emissions by 2050. They also have a long-term target to reduce Scope 1 and 2 GHG emissions by 97% per USD value added by 2050, which is equivalent to a 90% absolute reduction.

The company has demonstrated progress, achieving a 68% reduction in Scope 1 and 2 GHG emissions between 2009 and 2021. As of 2022, they reported being on track for their near-term targets. Boston Scientific was among the first medical device manufacturers to pledge carbon neutrality for its manufacturing and key distribution sites by 2030, a goal they are currently on track to meet. These targets have been approved by the Science Based Targets initiative (SBTi) under the Net-Zero Standard.